Ionis Pharmaceuticals, Inc. (IONS) Analysts See $-0.12 EPS

October 13, 2018 - By Michael Collier

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Logo

Analysts expect Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to report $-0.12 EPS on November, 6.After having $-0.05 EPS previously, Ionis Pharmaceuticals, Inc.’s analysts see 140.00 % EPS growth. The stock increased 3.76% or $1.63 during the last trading session, reaching $45. About 849,664 shares traded. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has declined 20.61% since October 14, 2017 and is downtrending. It has underperformed by 36.23% the S&P500.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company has market cap of $6.18 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and as an adjunct to lipid lowering medications and diet. It currently has negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug for transthyretin amyloidosis.

More notable recent Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news were published by: which released: “Biogen’s Spinraza shows positive effect in presymptomatic infants with SMA” on October 08, 2018, also with their article: “Akcea (AKCA), Ionis (IONS) Receive FDA Approval of TEGSEDI (Earlier)” published on October 07, 2018, published: “Roche’s risdiplam shows positive action in SMA studies” on October 03, 2018. More interesting news about Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) were released by: and their article: “Key events next week – healthcare” published on September 28, 2018 as well as‘s news article titled: “Meet Ionis Pharma’s Newest Collaboration” with publication date: October 10, 2018.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.